{"id":"cab-axl-adc","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4297987","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CAB-AXL-ADC combines a monoclonal antibody against AXL (a receptor tyrosine kinase) with a cytotoxic drug payload. Upon binding to AXL on tumor cells, the conjugate is internalized and releases the toxic payload to kill cancer cells. This approach aims to selectively target AXL-positive tumors while minimizing systemic toxicity.","oneSentence":"CAB-AXL-ADC is an antibody-drug conjugate that targets AXL-expressing cancer cells and delivers cytotoxic payload upon binding.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:25:30.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"AXL-positive solid tumors (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT04918186","phase":"PHASE2","title":"Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2022-05-03","conditions":"Ovarian Cancer","enrollment":60},{"nctId":"NCT04681131","phase":"PHASE2","title":"CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2021-03-17","conditions":"Non-Small-Cell Lung Cancer","enrollment":85},{"nctId":"NCT03425279","phase":"PHASE1, PHASE2","title":"CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2018-02-15","conditions":"Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma","enrollment":245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BA3011"],"phase":"phase_2","status":"active","brandName":"CAB-AXL-ADC","genericName":"CAB-AXL-ADC","companyName":"BioAtla, Inc.","companyId":"bioatla-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAB-AXL-ADC is an antibody-drug conjugate that targets AXL-expressing cancer cells and delivers cytotoxic payload upon binding. Used for AXL-positive solid tumors (Phase 2 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}